X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (13542) 13542
Publication (797) 797
Book Review (161) 161
Book Chapter (69) 69
Book / eBook (68) 68
Magazine Article (35) 35
Conference Proceeding (9) 9
Dissertation (6) 6
Newsletter (4) 4
Newspaper Article (3) 3
Trade Publication Article (3) 3
Government Document (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (8714) 8714
male (6857) 6857
female (5579) 5579
animals (4345) 4345
index medicus (4264) 4264
injections, intravenous (3751) 3751
infusions, intravenous (3450) 3450
middle aged (3435) 3435
adult (2882) 2882
aged (2549) 2549
pharmacology & pharmacy (1952) 1952
rats (1909) 1909
treatment outcome (1663) 1663
heparin - administration & dosage (1636) 1636
time factors (1559) 1559
cardiac & cardiovascular systems (1444) 1444
heparin (1229) 1229
dose-response relationship, drug (1171) 1171
heparin - therapeutic use (1102) 1102
peripheral vascular disease (1088) 1088
surgery (1051) 1051
pharmacokinetics (967) 967
hematology (944) 944
therapy (933) 933
intravenous administration (879) 879
prospective studies (856) 856
anticoagulants - administration & dosage (849) 849
anticoagulants - therapeutic use (841) 841
thrombolytic therapy (832) 832
analysis (830) 830
administration, oral (817) 817
risk factors (805) 805
rats, sprague-dawley (773) 773
care and treatment (761) 761
medicine, general & internal (746) 746
aged, 80 and over (715) 715
dogs (685) 685
mice (679) 679
myocardial infarction - drug therapy (675) 675
fibrinolytic agents - therapeutic use (654) 654
health aspects (652) 652
adolescent (651) 651
medicine & public health (650) 650
retrospective studies (636) 636
neurosciences (617) 617
molecular-weight heparin (614) 614
thrombosis (610) 610
anticoagulants (601) 601
research (599) 599
drug therapy (593) 593
heparin - pharmacology (577) 577
pregnancy (562) 562
follow-up studies (549) 549
drug administration schedule (548) 548
thrombolysis (547) 547
fibrinolytic agents - administration & dosage (542) 542
anesthesiology (520) 520
heparin - adverse effects (515) 515
drug therapy, combination (512) 512
mortality (504) 504
stroke (501) 501
injections, subcutaneous (499) 499
disease models, animal (489) 489
double-blind method (467) 467
management (462) 462
acute myocardial-infarction (455) 455
child (452) 452
rabbits (448) 448
acute disease (446) 446
endocrinology & metabolism (444) 444
ischemia (444) 444
blood pressure - drug effects (440) 440
clinical neurology (438) 438
trial (436) 436
rats, wistar (434) 434
metabolism (431) 431
pediatrics (427) 427
respiratory system (426) 426
blood (424) 424
patients (424) 424
recurrence (421) 421
prevention (410) 410
article (408) 408
physiology (408) 408
electrocardiography (407) 407
deep-vein thrombosis (404) 404
tissue plasminogen activator - therapeutic use (402) 402
anticoagulants - adverse effects (400) 400
intravenous unfractionated heparin (400) 400
administration, intravenous (398) 398
plasma (395) 395
tissue plasminogen activator - administration & dosage (395) 395
complications (390) 390
area under curve (385) 385
medicine (385) 385
dosage and administration (383) 383
half-life (383) 383
veterinary sciences (383) 383
physiological aspects (376) 376
immunology (372) 372
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (45) 45
Collection Dvlpm't (Acquisitions) - Closed Orders (4) 4
Scarborough Hospital - General (3) 3
Humber River Regional Hospital - Finch Stacks (2) 2
Lakeridge Health Sciences - Oshawa (2) 2
Providence Healthcare - Stacks (2) 2
Toronto East General Hospital - Stacks (2) 2
Dentistry (Harry R Abbott) - May be requested (1) 1
Dentistry (Harry R Abbott) - May be requested in 6-10 wks (1) 1
Gerstein Science - Missing (1) 1
Gerstein Science - Theses (1) 1
Humber River Regional Hospital - Church Stacks (1) 1
Markham Stouffville Hospital - Stacks (1) 1
Mt Sinai Hospital - Stacks (1) 1
Scarborough Hospital - Hospital Department (1) 1
Scarborough Hospital - Withdrawn (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
Trillium Health Centre - Stacks (1) 1
West Park Healthcare Centre - Stacks (1) 1
Women's College Hospital - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (13059) 13059
German (206) 206
French (155) 155
Russian (85) 85
Spanish (56) 56
Japanese (37) 37
Polish (32) 32
Italian (25) 25
Portuguese (11) 11
Chinese (8) 8
Czech (7) 7
Swedish (7) 7
Danish (5) 5
Korean (5) 5
Bulgarian (4) 4
Hungarian (4) 4
Norwegian (4) 4
Turkish (4) 4
Romanian (2) 2
Dutch (1) 1
Finnish (1) 1
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 05/1991, Volume 324, Issue 22, pp. 1565 - 1574
Journal Article
Circulation, ISSN 0009-7322, 2003, Volume 108, Issue 2, pp. 135 - 142
BACKGROUND: The combination of a single-bolus fibrinolytic and a low-molecular-weight heparin may facilitate prehospital reperfusion and further improve... 
Myocardial infarction | Reperfusion | Heparin | Fibrinolysis | Hemorrhage | MORTALITY | RETEPLASE | CARDIAC & CARDIOVASCULAR SYSTEMS | TISSUE-PLASMINOGEN ACTIVATOR | myocardial infarction | fibrinolysis | heparin | THERAPY | PERIPHERAL VASCULAR DISEASE | REOCCLUSION | reperfusion | INTERVENTION | hemorrhage | Injections, Intravenous | Humans | Middle Aged | Heparin - therapeutic use | Male | Risk | Tissue Plasminogen Activator - therapeutic use | Enoxaparin - therapeutic use | Heparin - adverse effects | Enoxaparin - adverse effects | Tissue Plasminogen Activator - adverse effects | Time Factors | Hemorrhage - etiology | Injections, Subcutaneous | Thrombolytic Therapy - methods | Female | Safety | Drug Therapy, Combination | Treatment Outcome | Emergency Medical Services - statistics & numerical data | Myocardial Infarction - drug therapy | Survival Analysis | Aged | Emergency Medical Services - methods | Thrombolytic Therapy - adverse effects | Cohort Studies | Hemorrhage/etiology | Enoxaparin/adverse effects/therapeutic use | Injections; Intravenous | Emergency Medical Services/methods/statistics & numerical data | Myocardial Infarction/drug therapy | Injections; Subcutaneous | Thrombolytic Therapy/adverse effects/methods | Drug Therapy; Combination | Research Support; Non-U.S. Gov't | Heparin/adverse effects/therapeutic use | Tissue Plasminogen Activator/adverse effects/therapeutic use
Journal Article
Journal Article
Journal Article
Circulation, ISSN 0009-7322, 07/1997, Volume 96, Issue 1, pp. 61 - 68
Background Low-molecular-weight heparin has a number of pharmacological and pharmacokinetic advantages over unfractionated heparin that make it potentially... 
heparin | MYOCARDIAL-INFARCTION | angina | myocardial infarction | COAGULATION | ASPIRIN | UMCG Approved | Myocardial infarction | Angina | Heparin | CARDIAC & CARDIOVASCULAR SYSTEMS | PERIPHERAL VASCULAR DISEASE
Journal Article
Journal of Thrombosis and Haemostasis, ISSN 1538-7933, 11/2017, Volume 15, Issue 11, pp. 2099 - 2114
Summary Autoimmune heparin‐induced thrombocytopenia (aHIT) indicates the presence in patients of anti‐platelet factor 4 (PF4)–polyanion antibodies that are... 
platelet factor 4 (PF4) | autoimmunity | platelet‐activating antibodies | heparin‐induced thrombocytopenia | high‐dose intravenous immunoglobulin | high-dose intravenous immunoglobulin | heparin-induced thrombocytopenia | platelet-activating antibodies | FACTOR 4/HEPARIN ANTIBODIES | FONDAPARINUX | WARFARIN THROMBOPROPHYLAXIS | IN-VITRO | CONFORMATIONAL-CHANGES | ORTHOPEDIC-SURGERY | CARDIAC-SURGERY | CROSS-REACTIVITY | PERIPHERAL VASCULAR DISEASE | PLATELET ACTIVATION | HEMATOLOGY | platelet factor4 (PF4) | CLINICAL-PRACTICE | Blood Platelets - immunology | Anticoagulants - administration & dosage | Administration, Oral | Autoantibodies - blood | Humans | Immunologic Factors - administration & dosage | Platelet Factor 4 - immunology | Immunoglobulins, Intravenous - administration & dosage | Anticoagulants - adverse effects | Heparin - adverse effects | Purpura, Thrombocytopenic, Idiopathic - blood | Purpura, Thrombocytopenic, Idiopathic - drug therapy | Heparin - immunology | Animals | Anticoagulants - immunology | Blood Coagulation - drug effects | Blood Platelets - metabolism | Partial Thromboplastin Time | Purpura, Thrombocytopenic, Idiopathic - immunology | Purpura, Thrombocytopenic, Idiopathic - chemically induced | Platelet Activation - drug effects | Blood Platelets - drug effects | Autoimmunity - drug effects | Thrombocytopenia | Autoimmunity | Fibrin | Medical examination | Immunoglobulin G | Anticoagulants (Medicine) | Sulfates | Blood | Anticoagulants | Immunoglobulins | Intravenous administration | Immune response | Disseminated intravascular coagulation | Polyphosphates | Catheters | Immunosuppressive agents | Recruitment | Thromboplastin | Platelet factor 4 | Polyanions | Side effects | Fibrinogen | Chondroitin sulfate | Heparin | Sulfate | Platelets | Antigen-antibody complexes
Journal Article